Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company develops, produces, and sells antibody drugs. Its products include YISAIPU, a tumor necrosis factor inhibitor type II-antibody fusion protein for the treatment of autoimmune rheumatism and immunology.

Its portfolio also includes Septin, an injection for anti-human epidermal growth factor receptor-2 treatment, and Jiannipa, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation. Founded in 2002, the company is based in Shanghai, China.